Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICT: GSK2132231A in Metastatic Melanoma
NCT00942162Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2009
- Primary completion
- Jun 2012
- Modality
- Vaccines & Immunotherapeutics, Peptides, Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 2 trial of astuprotimut-R in melanoma, sponsored by GSK. Started Aug 2009; status: completed.
02
Drugs
astuprotimut-R
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00942162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00942162.